Biosketch / Results /

James Goodrich

Clinical Instructor, Department of Medicine

Contact Info

212/545-9676


Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients
Gulick, Roy M; Fatkenheuer, Gerd; Burnside, Robert; Hardy, W David; Nelson, Mark R; Goodrich, James; Mukwaya, Geoffrey; Portsmouth, Simon; Heera, Jayvant R. Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients. Journal of acquired immune deficiency syndromes. JAIDS. 2014 Jan 1;65(1):78-81 (892942)

Successful treatment of post-shunt craniocerebral disproportion by coupling gradual external cranial vault distraction with continuous intracranial pressure monitoring
Sandler, Adam L; Daniels, Lawrence B 3rd; Staffenberg, David A; Kolatch, Eliezer; Goodrich, James T; Abbott, Rick. Successful treatment of post-shunt craniocerebral disproportion by coupling gradual external cranial vault distraction with continuous intracranial pressure monitoring. Journal of neurosurgery: Pediatrics. 2013 Mar 29;11(6):653-657 (387002)

Marvelous medicine: the untold story of the Wade-Dahl-Till valve
Sandler, Adam L; Sturrock, Donald; Branfield, Jane; Abbott, Rick; Goodrich, James T; Biswas, Arundhati; Daniels, Lawrence B 3rd; Flamm, Eugene S. Marvelous medicine: the untold story of the Wade-Dahl-Till valve [Historical Article]. Journal of neurosurgery: Pediatrics. 2012 May ;9(5):482-490 (454932)

Separation of craniopagus conjoined twins with a staged approach
Staffenberg, David A; Goodrich, James T. Separation of craniopagus conjoined twins with a staged approach. Journal of craniofacial surgery. 2012 Nov ;23(7 Suppl 1):2004-2010 (182542)

Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2
Hardy, W David; Gulick, Roy M; Mayer, Howard; Fatkenheuer, Gerd; Nelson, Mark; Heera, Jayvant; Rajicic, Natasa; Goodrich, James. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. Journal of acquired immune deficiency syndromes. JAIDS. 2010 Dec 15;55(5):558-564 (892742)